A systematic review of randomized controlled trials assessing the effect of Vortioxetine on metabolic syndrome risk indicators in patients with depression
Background: The majority of antidepressants have been reported to cause metabolic syndrome (MetS). Paucity of information available for the effect of Vortioxetine on MetS. The study aims to assess the systematic review of Vortioxetine on depressive patients' blood pressure (BP), central obesity...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Health Sciences Review |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772632023000557 |
| _version_ | 1797394788779032576 |
|---|---|
| author | Karthik Sankar Sushma Viswanathan Uma maheswari mugundan Roshini Kizhakkedeth Nazar Saranya Ramasamy Rajanandh Muhasaparur Ganesan |
| author_facet | Karthik Sankar Sushma Viswanathan Uma maheswari mugundan Roshini Kizhakkedeth Nazar Saranya Ramasamy Rajanandh Muhasaparur Ganesan |
| author_sort | Karthik Sankar |
| collection | DOAJ |
| description | Background: The majority of antidepressants have been reported to cause metabolic syndrome (MetS). Paucity of information available for the effect of Vortioxetine on MetS. The study aims to assess the systematic review of Vortioxetine on depressive patients' blood pressure (BP), central obesity, fasting plasma glucose (FPG), triglycerides (TGs), and high-density lipoprotein (HDL) levels, which are risk factors for the MetS. Methods: PRISMA guidelines were followed in conducting this systematic review. The protocol has been registered with PROSPERO (CRD42021272614). Randomized controlled trials (RCTs) that evaluated the effect of Vortioxetine on MetS risk indicators were searched in electronic databases. RCTs that included adult patients 18–75 years of age, Major depression patients (MDD) and prescribed with Vortioxetine drug. Preclinical research, editorials, letters, reviews, case reports, studies in pediatric populations, unpublished gray literature were excluded Abstract and title screening was performed, followed by full-text screening using the Covidence software. Data were extracted, and analysis was done using Cochrane Review Manager (RevMan v5.1). Results: Following the screening process, 8 RCTs (6 blinded and 2 open-label) were selected for systematic review. The MetS risk factors for Vortioxetine treatment in depressed patients were ambiguous from the available research. However, 4 of 8 RCTs have shown that Vortioxetine is an effective and safe treatment for depression. All the trials were methodological of high quality. Conclusions: A single study evaluating all the five MetS risk variables in depressed patients on Vortioxetine therapy is needed before recommending Vortioxetine as a first-line or switch therapy for depression. |
| first_indexed | 2024-03-09T00:24:48Z |
| format | Article |
| id | doaj.art-f20289a6599144ada94f495ebe0b3ab7 |
| institution | Directory Open Access Journal |
| issn | 2772-6320 |
| language | English |
| last_indexed | 2024-03-09T00:24:48Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Health Sciences Review |
| spelling | doaj.art-f20289a6599144ada94f495ebe0b3ab72023-12-12T04:37:17ZengElsevierHealth Sciences Review2772-63202023-12-019100129A systematic review of randomized controlled trials assessing the effect of Vortioxetine on metabolic syndrome risk indicators in patients with depressionKarthik Sankar0Sushma Viswanathan1Uma maheswari mugundan2Roshini Kizhakkedeth Nazar3Saranya Ramasamy4Rajanandh Muhasaparur Ganesan5Department of Pharmacy Practice, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Deemed to be University, Porur, Chennai, Tamil Nadu 600 116, IndiaDepartment of Psychiatry, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra Institute of Higher Education and Research, Deemed to be University, Porur, Chennai, Tamil Nadu 600 116, IndiaDepartment of Pharmacy Practice, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Deemed to be University, Porur, Chennai, Tamil Nadu 600 116, IndiaDepartment of Pharmacy Practice, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Deemed to be University, Porur, Chennai, Tamil Nadu 600 116, IndiaDepartment of Pharmacy Practice, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Deemed to be University, Porur, Chennai, Tamil Nadu 600 116, IndiaDepartment of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Deemed to be University, Kattankulathur, Chennai, Tamil Nadu 603 203, India; Corresponding author.Background: The majority of antidepressants have been reported to cause metabolic syndrome (MetS). Paucity of information available for the effect of Vortioxetine on MetS. The study aims to assess the systematic review of Vortioxetine on depressive patients' blood pressure (BP), central obesity, fasting plasma glucose (FPG), triglycerides (TGs), and high-density lipoprotein (HDL) levels, which are risk factors for the MetS. Methods: PRISMA guidelines were followed in conducting this systematic review. The protocol has been registered with PROSPERO (CRD42021272614). Randomized controlled trials (RCTs) that evaluated the effect of Vortioxetine on MetS risk indicators were searched in electronic databases. RCTs that included adult patients 18–75 years of age, Major depression patients (MDD) and prescribed with Vortioxetine drug. Preclinical research, editorials, letters, reviews, case reports, studies in pediatric populations, unpublished gray literature were excluded Abstract and title screening was performed, followed by full-text screening using the Covidence software. Data were extracted, and analysis was done using Cochrane Review Manager (RevMan v5.1). Results: Following the screening process, 8 RCTs (6 blinded and 2 open-label) were selected for systematic review. The MetS risk factors for Vortioxetine treatment in depressed patients were ambiguous from the available research. However, 4 of 8 RCTs have shown that Vortioxetine is an effective and safe treatment for depression. All the trials were methodological of high quality. Conclusions: A single study evaluating all the five MetS risk variables in depressed patients on Vortioxetine therapy is needed before recommending Vortioxetine as a first-line or switch therapy for depression.http://www.sciencedirect.com/science/article/pii/S2772632023000557Metabolic syndromeMetabolic risk parametersSerotonin modulatorMajor depressive disorderAntidepressant |
| spellingShingle | Karthik Sankar Sushma Viswanathan Uma maheswari mugundan Roshini Kizhakkedeth Nazar Saranya Ramasamy Rajanandh Muhasaparur Ganesan A systematic review of randomized controlled trials assessing the effect of Vortioxetine on metabolic syndrome risk indicators in patients with depression Health Sciences Review Metabolic syndrome Metabolic risk parameters Serotonin modulator Major depressive disorder Antidepressant |
| title | A systematic review of randomized controlled trials assessing the effect of Vortioxetine on metabolic syndrome risk indicators in patients with depression |
| title_full | A systematic review of randomized controlled trials assessing the effect of Vortioxetine on metabolic syndrome risk indicators in patients with depression |
| title_fullStr | A systematic review of randomized controlled trials assessing the effect of Vortioxetine on metabolic syndrome risk indicators in patients with depression |
| title_full_unstemmed | A systematic review of randomized controlled trials assessing the effect of Vortioxetine on metabolic syndrome risk indicators in patients with depression |
| title_short | A systematic review of randomized controlled trials assessing the effect of Vortioxetine on metabolic syndrome risk indicators in patients with depression |
| title_sort | systematic review of randomized controlled trials assessing the effect of vortioxetine on metabolic syndrome risk indicators in patients with depression |
| topic | Metabolic syndrome Metabolic risk parameters Serotonin modulator Major depressive disorder Antidepressant |
| url | http://www.sciencedirect.com/science/article/pii/S2772632023000557 |
| work_keys_str_mv | AT karthiksankar asystematicreviewofrandomizedcontrolledtrialsassessingtheeffectofvortioxetineonmetabolicsyndromeriskindicatorsinpatientswithdepression AT sushmaviswanathan asystematicreviewofrandomizedcontrolledtrialsassessingtheeffectofvortioxetineonmetabolicsyndromeriskindicatorsinpatientswithdepression AT umamaheswarimugundan asystematicreviewofrandomizedcontrolledtrialsassessingtheeffectofvortioxetineonmetabolicsyndromeriskindicatorsinpatientswithdepression AT roshinikizhakkedethnazar asystematicreviewofrandomizedcontrolledtrialsassessingtheeffectofvortioxetineonmetabolicsyndromeriskindicatorsinpatientswithdepression AT saranyaramasamy asystematicreviewofrandomizedcontrolledtrialsassessingtheeffectofvortioxetineonmetabolicsyndromeriskindicatorsinpatientswithdepression AT rajanandhmuhasaparurganesan asystematicreviewofrandomizedcontrolledtrialsassessingtheeffectofvortioxetineonmetabolicsyndromeriskindicatorsinpatientswithdepression AT karthiksankar systematicreviewofrandomizedcontrolledtrialsassessingtheeffectofvortioxetineonmetabolicsyndromeriskindicatorsinpatientswithdepression AT sushmaviswanathan systematicreviewofrandomizedcontrolledtrialsassessingtheeffectofvortioxetineonmetabolicsyndromeriskindicatorsinpatientswithdepression AT umamaheswarimugundan systematicreviewofrandomizedcontrolledtrialsassessingtheeffectofvortioxetineonmetabolicsyndromeriskindicatorsinpatientswithdepression AT roshinikizhakkedethnazar systematicreviewofrandomizedcontrolledtrialsassessingtheeffectofvortioxetineonmetabolicsyndromeriskindicatorsinpatientswithdepression AT saranyaramasamy systematicreviewofrandomizedcontrolledtrialsassessingtheeffectofvortioxetineonmetabolicsyndromeriskindicatorsinpatientswithdepression AT rajanandhmuhasaparurganesan systematicreviewofrandomizedcontrolledtrialsassessingtheeffectofvortioxetineonmetabolicsyndromeriskindicatorsinpatientswithdepression |